A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Nevirapine D4 | CAS 1051418-95-1 - Request Quote

Picture of Nevirapine D4

Nevirapine D4

SZ CAT No:SZ-N001D02
CAS No
1051418-95-1
Mol.F.
C15H10D4N4O
Mol.Wt.
270.3
Inv. Status
Synthesis on demand

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Nevirapine D4 is chemically 11-(Cyclopropyl-2,2,3,3-d4)-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one. Nevirapine D4 is supplied with detailed characterization data compliant with regulatory guideline. Nevirapine D4 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Nevirapine .

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

Buy 1051418-95-1

Purchase 1051418-95-1

Order 1051418-95-1

Enquire 1051418-95-1

price of 1051418-95-1

1051418-95-1 Supplier

1051418-95-1 Manufacturer

1051418-95-1 Exporter

buy high quality Nevirapine D4

Purchase Nevirapine D4

Nevirapine D4 suppliers

Nevirapine D4 manufacturers

Nevirapine D4 price

Order Nevirapine D4

Enquire Nevirapine D4

Nevirapine D4 cost

Nevirapine D4 Supplier

Nevirapine D4 Distributor

Nevirapine D4 for Method Validation

Nevirapine Reference Standard

Nevirapine D4 for ANDA Filing

Nevirapine D4 for Forced Degradation Studies

Nevirapine D4 Identification Standards

Nevirapine D4 for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,